PL334833A1 - Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity - Google Patents
Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesityInfo
- Publication number
- PL334833A1 PL334833A1 PL98334833A PL33483398A PL334833A1 PL 334833 A1 PL334833 A1 PL 334833A1 PL 98334833 A PL98334833 A PL 98334833A PL 33483398 A PL33483398 A PL 33483398A PL 334833 A1 PL334833 A1 PL 334833A1
- Authority
- PL
- Poland
- Prior art keywords
- thiazolobenzenosulphonamides
- obesity
- treating diabetes
- beta3
- agonists
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL334833A1 true PL334833A1 (en) | 2000-03-27 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL98334833A PL334833A1 (en) | 1997-01-28 | 1998-01-23 | Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (en) |
| JP (1) | JP2001509166A (en) |
| KR (1) | KR20000070568A (en) |
| CN (1) | CN1251099A (en) |
| AR (1) | AR011092A1 (en) |
| AU (1) | AU728812B2 (en) |
| BG (1) | BG103686A (en) |
| BR (1) | BR9807096A (en) |
| CA (1) | CA2278739A1 (en) |
| EA (1) | EA199900692A1 (en) |
| EE (1) | EE9900328A (en) |
| HR (1) | HRP980044A2 (en) |
| HU (1) | HUP0002053A3 (en) |
| ID (1) | ID22273A (en) |
| IL (1) | IL131130A0 (en) |
| IS (1) | IS5131A (en) |
| NO (1) | NO993646L (en) |
| PE (1) | PE52299A1 (en) |
| PL (1) | PL334833A1 (en) |
| SK (1) | SK100099A3 (en) |
| TR (1) | TR199902442T2 (en) |
| WO (1) | WO1998032753A1 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (en) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino azole compounds |
| CA2397554C (en) | 2000-01-21 | 2009-09-22 | Novartis Ag | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| EP1258253A1 (en) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| EP1138685B1 (en) | 2000-03-31 | 2004-05-19 | Pfizer Products Inc. | Process for preparing substituted pyridines |
| PL360098A1 (en) * | 2000-07-13 | 2004-09-06 | Eli Lilly And Company | Beta3 adrenergic agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| CA2421594A1 (en) | 2000-11-10 | 2002-05-16 | John Arnold Werner | 3-substituted oxindole beta 3 agonists |
| DE60139639D1 (en) * | 2000-12-08 | 2009-10-01 | Takeda Pharmaceutical | SUBSTITUTED THIAZONE DERIVATIVES WITH 3-PYRIDYL GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
| AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
| EP1404672B1 (en) * | 2001-06-22 | 2006-01-18 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1421078B1 (en) | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| ES2262817T3 (en) | 2001-08-14 | 2006-12-01 | Eli Lilly And Company | BETA-3 OXINDOL 3-SUBSTITUTED AGONISTS. |
| DE60208815T2 (en) * | 2001-10-12 | 2006-07-20 | Bayer Pharmaceuticals Corp., West Haven | PHENYL SUBSTITUTES 5-LOW NITROGEN-CONTAINING HETEROCYCLES FOR THE TREATMENT OF FAT ADJUSTMENT |
| WO2003044016A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
| AU2002353844A1 (en) | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| EP1467733A1 (en) | 2002-01-11 | 2004-10-20 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| WO2006132196A1 (en) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST |
| CN102908350B (en) | 2005-09-14 | 2014-07-23 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors for treating diabetes |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| EP1937264B1 (en) | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| JP5489333B2 (en) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | Methods of treatment using fatty acid synthesis inhibitors |
| CA2682727C (en) | 2007-04-02 | 2016-03-22 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
| CA2688161C (en) | 2007-06-04 | 2020-10-20 | Kunwar Shailubhai | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (en) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others |
| AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| US8802695B2 (en) | 2010-02-03 | 2014-08-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| BR112015002080A2 (en) | 2012-08-02 | 2017-07-04 | Merck Sharp & Dohme | compound, pharmaceutical composition, use of a compound, and method of treating or preventing a disorder, condition or disease |
| ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| MX2015010935A (en) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Antidiabetic bicyclic compounds. |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| JP2016514670A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase receptor agonists in combination with other drugs |
| SI3004138T1 (en) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/en unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/en unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/en unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/en not_active Withdrawn
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/en unknown
- 1998-01-23 IL IL13113098A patent/IL131130A0/en unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 SK SK1000-99A patent/SK100099A3/en unknown
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 ID IDW990755A patent/ID22273A/en unknown
- 1998-01-23 EA EA199900692A patent/EA199900692A1/en unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/en not_active IP Right Cessation
- 1998-01-23 JP JP53214898A patent/JP2001509166A/en active Pending
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 CN CN98803585A patent/CN1251099A/en active Pending
- 1998-01-27 AR ARP980100357A patent/AR011092A1/en unknown
- 1998-01-28 PE PE1998000064A patent/PE52299A1/en not_active Application Discontinuation
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/en not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/en unknown
- 1999-07-27 NO NO993646A patent/NO993646L/en not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998032753A1 (en) | 1998-07-30 |
| IL131130A0 (en) | 2001-01-28 |
| AU728812B2 (en) | 2001-01-18 |
| ID22273A (en) | 1999-09-23 |
| NO993646D0 (en) | 1999-07-27 |
| KR20000070568A (en) | 2000-11-25 |
| EE9900328A (en) | 2000-02-15 |
| BR9807096A (en) | 2000-04-18 |
| AU6038498A (en) | 1998-08-18 |
| TR199902442T2 (en) | 2000-07-21 |
| EA199900692A1 (en) | 2000-02-28 |
| AR011092A1 (en) | 2000-08-02 |
| IS5131A (en) | 1999-07-23 |
| CA2278739A1 (en) | 1998-07-30 |
| BG103686A (en) | 2000-06-30 |
| CN1251099A (en) | 2000-04-19 |
| SK100099A3 (en) | 2000-05-16 |
| JP2001509166A (en) | 2001-07-10 |
| EP0968209A1 (en) | 2000-01-05 |
| HRP980044A2 (en) | 1998-10-31 |
| PE52299A1 (en) | 1999-05-26 |
| HUP0002053A2 (en) | 2001-08-28 |
| HUP0002053A3 (en) | 2001-09-28 |
| NO993646L (en) | 1999-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL334833A1 (en) | Thiazolobenzenosulphonamides as beta3 agonists for treating diabetes and obesity | |
| EP0915847A4 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| HU9602951D0 (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| AU3374897A (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| GR20010300044T1 (en) | Transfected cells and methods for treating diabetes | |
| AU8693098A (en) | Compositions and methods for treating diabetes | |
| IL122718A0 (en) | Methods for treating diabetes | |
| ZA981343B (en) | Sulfonylurea-glitazone combinations for diabetes | |
| EP0996497A4 (en) | Device and process for liquid treatment | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| PL338082A1 (en) | Methods of treating obesity | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| HUP0101779A3 (en) | Process for de-chlorinating and de-fouling waste-oil | |
| ZA200006866B (en) | Device and method for treating electroconductive endless material. | |
| GB9606076D0 (en) | Diabetes treatment | |
| GB2322184B (en) | Thermal treatment apparatus | |
| IL145220A0 (en) | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process | |
| EP1007041A4 (en) | Composition for treating pain | |
| HUP0003187A3 (en) | Substituted benzothiophenes and process for preparing them | |
| EP0719556A3 (en) | Agent for treating diabetic keratopathy | |
| GB9717251D0 (en) | Process and apparatus | |
| EP1161242A4 (en) | Composition and method for treating diabetes | |
| GB9605164D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| EP0959110A4 (en) | Material and process for surface treatment | |
| GB9705041D0 (en) | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |